The protective blood–brain barrier has a major role in ensuring normal brain function by
severely limiting and tightly controlling the ingress of substances into the brain from the …

Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …

Brain metastases are a very common manifestation of cancer that have historically been
approached as a single disease entity given the uniform association with poor clinical …

The blood-brain barrier (BBB) is an important factor limiting the effectiveness of central
nervous system (CNS) therapeutics. MR-guided focused ultrasound (MRgFUS) is a …

Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) blockade is effective in a subset of
patients with several tumor types, but predicting patient benefit using approved diagnostics …

Brain metastases from breast cancer (BCBM) constitute the second most common cause of
brain metastasis (BM), and the incidence of these frequently lethal lesions is currently …

The incidence of brain metastases has markedly increased in the past 20 years owing to
progress in the treatment of malignant solid tumours, earlier diagnosis by MRI and an …

Background Patients with metastatic breast cancer (MBC) are living longer, but the
development of brain metastases often limits their survival. We conducted a systematic …

Purpose: Therapeutic nanoparticles are designed to deliver their drug payloads through
enhanced permeability and retention (EPR) in solid tumors. The extent of EPR and its …

The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable
success in recent years. Antibody–drug conjugates are powerful new treatment options for …